Miriã Cândida Oliveira

Dr. Miriã Cândida Oliveira

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
SMSandra M. B. P. Moreira
Sandra M. B. P. Moreira
Andre BachiAndre Bachi
Andre Bachi
EIElias Jirjoss Ilias
Elias Jirjoss Ilias
CMCarlos Alberto Malheiros
Carlos Alberto Malheiros
SVSergio Vencio
Sergio Vencio
LOLuis V F Oliveira
Luis V F Oliveira
Obesity is a troubling public health problem as it increases risks of sleep disorders, respiratory complications, systemic arterial hypertension, cardiovascular diseases, type 2 diabetes mellitus, and metabolic syndrome (MetS). As a measure to counteract comorbidities associated with severe obesity, bariatric surgery stands out. This study aimed to investigate the adiponectin/leptin ratio in women with severe obesity with and without MetS who had undergone Roux-en-Y gastric bypass (RYGB) and to characterize the biochemical, glucose, and inflammatory parameters of blood in women with severe obesity before and after RYGB. Were enrolled females with severe obesity undergoing RYGP with MetS (n = 11) and without (n = 39). Anthropometric data and circulating levels of glucose, total cholesterol, high-density lipoprotein (HDL), non-HDL total cholesterol, low-density lipoprotein (LDL), adiponectin, and leptin were assessed before and 6 months after RYGB. Significant reductions in weight, body mass index, and glucose, total cholesterol, LDL, and leptin were observed after surgery, with higher levels of HDL, adiponectin, and adiponectin/leptin ratio being observed after surgery compared to the preoperative values of those. This study demonstrated that weight loss induced by RYGB in patients with severe obesity with or without MetS improved biochemical and systemic inflammatory parameters, particularly the adiponectin/leptin ratio.

MOMiriã Cândida Oliveira
Miriã Cândida Oliveira
LALarissa R. Alves
Larissa R. Alves
JSJuliana Soares
Juliana Soares
SSShayra K. A. Souza
Shayra K. A. Souza
BSBruna M. R. Silva
Bruna M. R. Silva
LOLuis V F Oliveira
Luis V F Oliveira
Background: COVID-19 mainly affects the respiratory system, although its manifestations are multisystemic. We are increasingly recognizing complications that present after the acute phase, which are associated with impaired functional status and health-related quality of life (HRQoL). The objective was to assess the functional status and HRQoL of patients with post-COVID-19. Methods: This was a cross-sectional study involving individuals affected by COVID-19 who had persistent symptoms for one month after the acute phase of the disease. Functional status was measured with the six-minute walk test (6MWT), the Fatigue Severity Scale (FSS), the Medical Research Council (MRC) Dyspnea Scale, and the Post-COVID-19 Functional Status Scale (PCFS). HRQoL was confirmed with the Short-Form Health Survey 36 (SF-36). Results: We included 123 patients; 73 (59.35%) were male, with a mean age of 49.17 ± 13.48 years and a body mass index of 31.02 ± 6.56 stratified into three groups: the not-recovered group (NRG = 23), the ward-recovered group (WHG = 60), and the intensive-care-unit group (ICUG = 40). The main symptoms were muscle weakness (74.17%) and dyspnea (68.33%). The predicted distances for the 6MWT were missed by 12.83% by the GNR group, 20.21% by the GNR group, and 28.82% by the UGCI group. The MRC dyspnea scale had a mean value of less than 3, and the FSS scale had a mean value of over 4, indicating considerable fatigue. In the PCFS scale, a significant difference was observed (p < 0.0005), while in the SF-36, all HRQoL domains were compromised. Conclusion: Post-COVID-19 patients involved in this study showed a significant decline in functional status and an impairment of HRQoL.

23 September 2021 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
ASAlan Robson Trigueiro de Sousa
Alan Robson Trigueiro de Sousa
WJWilson R. Freitas Júnior
Wilson R. Freitas Júnior
EPEduardo Araujo Perez
Eduardo Araujo Perez
EIElias Jirjoss Ilias
Elias Jirjoss Ilias
ASAnderson Soares Silva
Anderson Soares Silva
LOLuis V F Oliveira
Luis V F Oliveira

22 September 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
VMVinicius Zacarias Maldaner
Vinicius Zacarias Maldaner
JCJean Coutinho
Jean Coutinho
ASAlfredo Nicodemos da Cruz Santana
Alfredo Nicodemos da Cruz Santana
GCGraziella F B Cipriano
Graziella F B Cipriano
MOMiriã Cândida Oliveira
Miriã Cândida Oliveira
GCGerson Cipriano
Gerson Cipriano
Introduction A significant number of patients with COVID-19 may experience dyspnoea, anxiety, depression, pain, fatigue and physical impairment symptoms, raising the need for a multidisciplinary rehabilitation approach, especially for those with advanced age, obesity, comorbidities and organ failure. Traditional pulmonary rehabilitation (PR), including exercise training, psychosocial counselling and education, has been employed to improve pulmonary function, exercise capacity and quality of life in patients with COVID-19. However, the effects of inspiratory muscle training (IMT) in PR programmes remain unclear. This study aimed to determine whether the addition of a supervised IMT in a PR is more effective than PR itself in improving dyspnoea, health-related quality of life and exercise capacity in symptomatic patients with post-COVID-19. Methods and analysis This parallel-group, assessor-blinded randomised controlled trial, powered for superiority, aimed to assess exercise capacity as the primary outcome. A total of 138 are being recruited at two PR centres in Brazil. Following baseline testing, participants will be randomised using concealed allocation, to receive either (1) standard PR with sham IMT or (2) standard PR added to IMT. Treatment effects or differences between the outcomes (at baseline, after 8 and 16 weeks, and after 6 months) of the study groups will be analysed using an ordinary two-way analysis of variance. Ethics and dissemination This trial was approved by the Brazilian National Ethics Committee and obtained approval on 7 October 2020 (document number 4324069). The findings will be disseminated through publications in peer-reviewed journals and conference presentations. Trial registration number NCT04595097.

25 October 2025 in COVID
Verified
Journal Article
Open access
PDF file
MCMarilúcia M. Carrijo
Marilúcia M. Carrijo
MOMiriã Cândida Oliveira
Miriã Cândida Oliveira
WCWashington A. O. Canedo
Washington A. O. Canedo
JAJoão Pedro Ribeiro Afonso
João Pedro Ribeiro Afonso
HPHeren N. C. Paixão¹˒³˒⁴
Heren N. C. Paixão¹˒³˒⁴
LOLuis V F Oliveira
Luis V F Oliveira
Global estimates show a 17.9% prevalence of neuropsychiatric disorders in individuals recently hospitalized with COVID-19. Cognitive behavioral therapy (CBT) has been proposed as a nonpharmacological strategy to mitigate these effects. This study examined the potential effects of CBT on anxiety, depression, post-traumatic stress disorder (PTSD), and quality of life (QoL) in post-COVID-19 patients. This prospective, nonrandomized, single-center clinical trial involved 15 patients (mean age 53.4 years) who underwent weekly CBT sessions for six weeks. Between-group differences in anxiety and depression scores were non-significant (p > 0.05); however, significant intragroup improvements were observed in anxiety (p = 0.01), depression (p = 0.01), and PTSD (p = 0.01) after the intervention. Thus, CBT was associated with reduced anxiety, depression, and PTSD as well as improved quality of life in post-COVID-19 patients. Improvements in QoL were noted mainly in the domains of functional capacity, vitality, emotional aspects, and mental health. While these findings suggest that CBT may be beneficial for post-COVID-19 patients, the small sample size, absence of a control group, and short follow-up period limit the strength of our conclusions. Therefore, the results should be considered preliminary, and further randomized controlled trials with larger sample sizes are warranted.

31 October 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
MOMiriã Cândida Oliveira
Miriã Cândida Oliveira
LALarissa Alves
Larissa Alves
JSJuliana Soares
Juliana Soares
SSShayra Souza
Shayra Souza
AFAdriano Fonseca
Adriano Fonseca
BSBruna Silva
Bruna Silva
Background: COVID-19 mainly affects the respiratory system, although its manifestations are multisystemic. Increasingly, complications presented after the acute phase are still being rec-ognized and are associated with impaired functional status and health-related quality of life (HRQoL). The objective was assess the functional status and HRQoL of patients with post-COVID-19. Methods: This was a cross-sectional study involving individuals affected by COVID-19 who had persistent symptoms for one month after the acute phase of the disease. HRQoL was verified through the Short Form Health Survey 36 (SF-36) and, functional status was assessed using the six-minute walk test (6MWT), the Fatigue Severity Scale (FSS), the Med-ical Research Council (MRC) Dyspnea Scale and, the Post-COVID-19 Functional Status Scale (PCFS). Results: Were included 123 patients, 73 (59.35%) were male, with a mean age of 49.17±13.48 years and a body mass index of 31.02±6.56 stratified into three groups, not recov-ered group (NRG=23), ward recovered group (WHG=60), and intensive care unit group (ICUG=40). The main symptoms were muscle weakness (74.17%) and dyspnea (68.33%). In rela-tion to the distance covered in the 6MWT, the GNR group walked 12.83% below the predicted values, GNR 20.21% and the UGCI 28.82%, respectively. The MRC dyspnea scale had a mean value of less than 3 and the FSS scale had a mean value over 4, indicating considerable fatigue. In the PCFS scale, a significant difference was observed (p>0.0005); while in the SF-36, all HRQoL domains were compromised. Conclusion: Post-COVID-19 patients involved in this study showed a significant decline in functional status and an impairment of HRQoL.